Search 

Cross border life science accelerator and angel investor based in San Francisco Bay Area and Wuxi, China.

Health & Life Science Cluster Bulgaria (www.biocluster.bg) has been founded three years ago to unify the efforts of experts, scientists, practitioners, researchers, academic institutions, startups, globally established companies, incubators, technology transfer companies, journalists, marketing and PR experts, who work for the advancement of biotechnology and life sciences field in Bulgaria.

The cluster successfully partners with a number of institutions and organizations, including Ministry of Economic, Ministry of education, BSMEPA, Sofia Municipality, Stara Zagora Municipality, Varna local authorities, Sofia Tech Park, BCCI, BESCO, Bulgarian Investment Agency, Medical University of Plovdiv, Medical University of Varna, Trakia University in Stara Zagora, CFA Bulgaria, EEN, Premium coworking spaces, PARA, United drone society, and many others.

The cluster participates in the establishment and the Management Board of the Association Bioscientific Society Bulgaria, which aims to support the development of the biosciences in Bulgaria and consolidation of a unified society of representatives of the Bulgarian bioscience community, working and studying both within Bulgaria and abroad. The cluster is a member of the Board of BRAIT (Bulgarian Employers' Association for Innovation and Technology, which is legal successor of the Bulgarian cluster association), together with Automotive Cluster, Mechatronics Cluster, BAIT, BASCOM, ICT Cluster and others.

The founding members of the cluster are into the core of the creation of The AI Cluster Bulgaria (www.aicluster.bg) in order to stimulate and create high value cross industry projects.

One of the objectives of the cluster is to stimulate, validate and promote technological progress in the sector of health & life sciences, as well as to connect scientists with business leaders, academia and media. Therefor Club Biotechnology & Life Sciences was founded at the beginning of 2020 in a collaboration with Sofia Tech Park.

The Cluster focuses its efforts on the development of a technology program at all levels: regional, national, and international.

Helsinn is a privately-owned Swiss Pharma Company which, since 1976, has been improving the lives of patients, guided by core family values of respect, integrity and quality. The Group has an extensive portfolio of On the market innovative cancer and rare disease therapies, a robust drug development pipeline and ambitions to further accelerate its growth through Licensing-in and acquisition to address unmet medical needs. Helsinn operates a unique integrated licensing business model, achieving success with over 80 long-standing partners in 190 countries, who share our values. The Group’s pharmaceutical business, (Helsinn Healthcare) is headquartered in Lugano, Switzerland with operating subsidiaries in the U.S. (Helsinn Therapeutics US) and China (Helsinn Pharmaceuticals China) which market the Group’s products directly in these countries. The Group has additional operating subsidiaries in Switzerland (Helsinn Advanced Synthesis, an active pharmaceutical ingredient manufacturer) and Ireland (Helsinn Birex Pharmaceuticals, a drug product manufacturer). Helsinn Investment Fund was created to enhance the future of healthcare by providing funding and strategic support to innovative companies.

We are into Mabs - Biosimilars

Hong Kong Biotechnology Organization is an independent nonprofit organization with the goal to promote best practice, raise awareness across the biotechnology industry while providing added value benefits to its members, whether they are students, researchers, entrepreneurs, industry bodies, public or private sector representatives.

Founded by pioneering scientists with extensive life science backgrounds and multi-cultural experience in research and development, engineering and business. Hong Kong Biotechnology Organization aims to establish and facilitate a worldwide platform for the Hong Kong biotech industry, promote awareness, encouraging and enabling international collaboration. We also provide informed opinion and technical advice to government bodies, healthcare institutions and the general public.

Idience Co. Ltd. (“Idience’) is a NRDO (No Research & Development Only) company focusing on oncology treatment. The company was established in 2019 by Ildong Holdings Group, a holding company of leading pharmaceutical and healthcare companies in South Korea.

Our first asset, IDX-1197 is a PARP inhibitor for various solid cancers including breast cancer and ovarian cancer. Its ongoing Phase 1a multi-center study showed a promising result. In October 2019, Idience received approval for its initial Investigational New Drug (IND) application from the Korea Ministry of Food and Drug Safety to start a Phase 1b/2a clinical trial for IDX-1197.

Idience is looking for corporate partners to discover and develop oncology therapeutics. We are open to all license-in and license-out partners.

Illumina is a provider of Next Generation Sequencing technology

Illumina Ventures is an independently managed firm focused on early-stage companies that are pioneering new applications of genomics and enabling precision medicine. Illumina Ventures invest in life science tools, clinical diagnostics, therapeutics, and other opportunities to improve human health.